Navigation Links
New anti-cancer agents show promise for treating aggressive breast cancers
Date:7/18/2011

Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.

ABT-737 is one of a new class of anti-cancer agents called BH3 mimetics that target and neutralise the so-called Bcl-2 proteins in cancer cells. Bcl-2 proteins act to 'protect' the cells after they have been damaged by chemotherapy drugs, and prevent the cancer cells from dying.

Professors Geoff Lindeman and Jane Visvader, who led the research with colleagues Dr Samantha Oakes and Dr Franois Vaillant from the institute's Stem Cells and Cancer division, said that the BH3 mimetics showed promise for treating breast cancers, including 'triple negative' cancers. Their research is published today in the Proceedings of the National Academy of Sciences USA.

Triple negative breast cancers are so-called because they test negative for oestrogen, progesterone and HER2 receptors, and cannot be treated with hormone therapy or trastuzumab. They account for up to 20 per cent of all breast cancers and are typically aggressive with a poor prognosis.

Dr Lindeman said that early results suggest navitoclax (an orally-available BH3 mimetic) could provide new hope for treating some breast cancers that are not candidates for other currently available treatments.

"ABT-737 targets proteins from the Bcl-2 family, which are found at high levels in up to 70 per cent of breast cancers," Dr Lindeman said. "We have shown that breast tumours that have high levels of Bcl-2 respond well to treatment with ABT-737 when used in combination with a conventional chemotherapy drug."

ABT-737 and navitoclax were discovered by Abbott scientists and are based on the discovery made at the Walter and Eliza Hall Institute in the 1980s that Bcl-2 is a 'pro-survival' protein responsible for preventing cell death in healthy and diseased cells
'/>"/>

Contact: Liz Williams
williams@wehi.edu.au
61-405-279-095
Walter and Eliza Hall Institute
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Garden-Grown Rhubarb May Have Anti-Cancer Properties
2. Overcoming tumor resistance to anti-cancer agent TRAIL
3. UNC study offers first clinical evidence of anti-cancer drug triggering viral infection
4. ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
5. Program focuses on anti-cancer stem cell therapies
6. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
7. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
8. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
9. Researchers advance biosynthesis of potent anti-cancer drug Taxol
10. Parkinsons disease: Excess of special protein identified as key to symptoms and possible new target for treatment with widely used anti-cancer drug imatinib
11. Soft drink could enhance effects of an anti-cancer drug
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New anti-cancer agents show promise for treating aggressive breast cancers
(Date:7/29/2014)... 2014 The Law Offices of Michael Cordova ... Hope, a non-profit organization providing grief camps for kids, teens, ... and suffering our clients experience from the death of a ... an organization like Stepping Stones of Hope, as they provide ... Stones of Hope also includes a monthly support group and ...
(Date:7/29/2014)... record the severity and regularity of their pain is ... , A new approach to the treatment of headaches, ... and is being led by Professor Paul Martin from ... He has developed an approach designed to enable people ... Learning to Cope with Triggers (LCT). , Using a ...
(Date:7/29/2014)... of cancer is to surgically remove the tumor. The ... surgeon may fail to extract the entire tumor, leading ... researchers at the University of Pennsylvania have established a ... in the patient, increasing the likelihood of a positive ... accumulates in cancerous tissues much more so than normal ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 A new ... during the 2014 Society for Cardiovascular Angiography and Interventions ... released this week. The videos review the benefits of ... services for the cardiac catheterization laboratory from the perspective ... the first video, Jane Kiah, MS, RN, Director of ...
(Date:7/29/2014)... boys with fragile X syndrome tend to decline ... of the inherited disorder to date has found. ... social and practical skills, including communication, socialization, and ... dressed. In this study, socialization emerged as a ... that it did not decline as much as ...
Breaking Medicine News(10 mins):Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3Health News:Accreditation for Cardiovascular Excellence (ACE) Launches 3-Part Video Series: The Cost/Benefit of ACE Accreditation; ProMedica Toledo Hospital Achieves Accreditation 2Health News:Accreditation for Cardiovascular Excellence (ACE) Launches 3-Part Video Series: The Cost/Benefit of ACE Accreditation; ProMedica Toledo Hospital Achieves Accreditation 3Health News:Socialization relative strength in fragile X longitudinal study 2
... up with a remarkable discovery. Scientists there, have found ... have added benefits. Sildenafil and other drugs that help to ... chemical messenger seem to help in unveiling cancer cells. ... by that the immune system. , The ...
... Dr. Reddy's Laboratories will launch a first-of-its-kind pill to ... it was announced Thursday. // ,The company ... New Zealand, for trials of the groundbreaking 'polypill' that ... to treat heart ailments. , ,India records nearly ...
... multi vitamin supplements have a healthier diet and lifestyle ... ,Researchers led by Lindsay Reaves of the University of ... weight, diet and health behaviour of over 2,500 US ... , ,The study, which appeared in the December ...
... areas as part of a government plan to reach healthcare ... government has released initial funds to the tune of Rs. ... in rural areas. ,According to a health ministry ... Health Mission (NRHM) scheme for 2006-07. ,The ...
... is admissible to Orthopaedically Handicapped/Paraplegic persons, Completely Blind, ... (both afflictions together in the same person). Except ... all classes to other categories. Deaf & Dumb ... and First Class. Concession is granted in all ...
... The American Dental association announced on the 9th of November, ... preparation of infant formulation. // ,The dentists are concerned ... might be disastrous as instead of protecting teeth it might ... lead to weakened bones and even bone cancer boys. ...
Cached Medicine News:Health News:Impotency Drugs Help to Unmask Cancer Cells 2Health News:Dr. Reddy's To Launch 'Polypill' For Treating Heart Disease 2
(Date:7/29/2014)... SAN DIEGO , July 29, 2014  Neurocrine ... that the Company will report its second quarter 2014 ... August 6, 2014.  Neurocrine will then host a live ... and provide a Company update Thursday morning, August 7, ... Time). Participants can access the live conference ...
(Date:7/29/2014)... TORONTO , July 29, ... ESAQ), an emerging pharmaceutical company exploring drug ... novel formulations and alternative dosage forms of ... its pharmaceutical development implementing its sub-micron platform technology.  ... drugs that will address indications in diabetes ...
(Date:7/29/2014)... LINCOLNSHIRE, Ill. , July 29, 2014  Sysmex ... equipment and information systems technology, will feature an exhibit ... (AACC) Annual Meeting and Clinical Lab Expo in ... 31, 2014. "We are extremely excited ... tremendous opportunity to interact with our customers and continue ...
Breaking Medicine Technology:Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3
... The Hancock® II bioprosthesis from ... years of proven clinical experience. ... the freedom from structural valve ... and mitral bioprostheses is substantially ...
... bioprosthesis from Medtronic has more ... clinical experience. Worldwide clinical studies ... structural valve deterioration with Hancock® ... is substantially better than results ...
Attain Venogram Balloon Catheter....
... cardioverter defibrillators (ICDs) are designed to treat ... (SCD) due to arrhythmia. The size and ... is designed to facilitate ease of insertion ... 2 system incorporates Guidant's proprietary RHYTHM ID ...
Medicine Products: